We provide expert tailor-made partnerships for innovative companies.
Sanofi Active Ingredient Solutions is a contract development and manufacturing organisation (CDMO) specialising in active pharmaceutical ingredient (API) supply and custom synthesis.
The company is the new branding of Sanofi API third party business. More than 2,000 women and men are developing, manufacturing and supplying API and technological solutions for external customers and partners in 80 countries.
To do so, the company works with passion, pride and rigour, recognising that its products are the key contributor to therapeutic solutions, helping millions of people live life to its full potential, every day, all over the world.
For innovative pharmaceutical companies, from start-ups to big pharma companies, generics pure players and through its catalogue of high-quality active ingredients and its contract development and manufacturing organisation, the company delivers expertise and customised solutions that contribute to the success of your business.
Sanofi Active Ingredient Solutions
As a global leader, Sanofi Active Ingredient Solutions has been supporting customers for decades with innovative, efficient and safe solutions, high-quality products and premium customer service.
Contract development and manufacturing services for medical drugs
Sanofi Active Ingredient Solutions offers pharmaceutical drug developers in more than 80 countries with API and technological solutions, supporting partners from process development to regulatory submission.
Its expertise covers multiple therapeutic areas for human and animal health, including corticosteroids, hormones, viral vectors, multi-step chemistry, opiates, prostaglandins and high-active products, as well as plasmids, oligosaccharides, peptides, oligosaccharides, biotechnologies and monoclonal antibodies (mAb).
Sanofi Active Ingredient Solutions partners with innovative companies ranging from start-ups to some of the biggest pharmaceutical players. Its catalogue of high-quality APIs and customised CDMO services delivers expertise and contributes to key therapeutic solutions that help millions of people.
The company has been supporting customers for decades with innovative, efficient and safe solutions, as well as high-quality products and customer service. It focuses on the continuous improvement of manufacturing processes to optimise output and meet client expectations.
Sanofi Active Ingredient Solutions’ synthesis API portfolio covers cardiovascular disease, metabolic disorders, analgesics and non-fluorinated glucocorticoids and derivatives (NSAID), as well as central nervous system (CNS) disorders and anaesthetics.
In the corticosteroids and hormones field, the company has more than 60 years of experience, and is a fully integrated corticoids manufacturer.
Clinical supply and commercial manufacturing for the biotech industry
Sanofi Active Ingredient Solutions has been providing biotech customers with services ranging from clinical supply to commercial manufacturing since 1985. Using its dedicated biotech platform, the company has gained a significant track record, working on an average of more than 70 batches per year.
The company has 25 years of experience in the field of oligosaccharides. Sanofi Active Ingredient Solutions’ analytical expertise guarantees purity and quality, while its robust supply chain is widely recognised.
Fermentation technologies, nutraceuticals, vitamins and probiotics
Sanofi Active Ingredient Solutions offers large-volume fermentation services and has proven expertise in nutraceuticals, vitamins and probiotics.
The company meets clients’ specific demands with the highest standards.
It has a long-standing expertise in organic chemistry with specific competencies in complex and long synthesis, as well as supports its customers’ projects from early phases through to validation campaigns.
APIs for human and animal health
Sanofi Active Ingredient Solutions is a world leader in the manufacturing of prostaglandins, with a strong historical background in process development and the scale-up of new chemical entities. Its portfolio includes 18 prostaglandin APIs.
The company’s production lines are multi-purpose, allowing quick and flexible developments and scale-ups, along with constant high quality. It also provides exhaustive regulatory support to its customers.
Sanofi Active Ingredient Solutions is the sole European vitamin B12 manufacturer, while its biotech API catalogue offers 14 APIs, including antibiotics and anti-tuberculosis.
Beyond the APIs, the company has developed a strong customer-oriented policy with a large range of possible specifications and customisations.
Opiates from poppy seeds to APIs
Sanofi Active Ingredient Solutions provides opiates in forms ranging from poppy seeds to APIs.
The company’s portfolio comprises 15 opiate APIs with applications in agronomic research, industrial and agricultural production, and distribution. It grows and harvests 10,000 ha of poppies each year.
Sanofi's production network is a living reflection of our diversified portfolio, different technologies, various scales of operations, a vast geographical reach and different therapeutic ideas.
Sanofi Active Ingredient Solutions have more than 2,000 people developing, manufacturing and supplying active pharmaceutical ingredients and technological solutions to external customers and partners in 80 countries.
This white paper showcases Sanofi Active Ingredient Solution's product list for 2018.
French pharmaceutical company Sanofi’s manufacturing facility in Goa, India, is located in the Verna Industrial Park, owned by Sanofi’s Indian arm Sanofi India, previously known as Aventis Pharma.
Switzerland-based biopharmaceuticals supplier Lonza and French life sciences firm Sanofi have established a joint venture (JV) to set up a large-scale biologics production facility in Visp, Switzerland.
France-based pharmaceutical company Sanofi is expanding its biologics plant in Geel, Belgium, to add to its manufacturing and commercial production capabilities.
Sanofi China opened a new assembling and packaging facility for prefilled insulin devices in Beijing, China, in May 2012. The facility will produce the SoloSTAR insulin injection pens.
Sanofi and GSK are pleased to announce that they have signed a letter of intent to develop an adjuvanted vaccine for Covid-19, using new technology from both companies, to aid in addressing the ongoing pandemic.
Sanofi and Regeneron Provide Update on US Phase 2/3 Adaptive-Designed Trial in Hospitalised Covid-19 Patients
Sanofi and Regeneron Pharmaceuticals have announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial investigating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalised patients with serious respiratory illness as a result of Covid-19.
Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any drug.
Sanofi is pleased to announce that it will be appearing at CPhI Japan on 16-18 March at Tokyo Big Sight in Tokyo, Japan.
Sanofi Active Ingredient Solutions are pleased to announce we will be appearing at CPhI Worldwide on 5-7 November at Messe Frankfurt in Frankfurt, Germany.
AGuIX® is an innovative nanoparticle discovered by NH TherAGuIX, a French start-up based in Lyon and created in 2015 by Géraldine Le Duc and Olivier Tillement.
Sanofi CEPiA has announced that the company will now be known as Sanofi Active Ingredient Solutions.
Sanofi has announced it will be attending a number of events this year.
Sanofi CEPiA has announced a number of upcoming events where the company will be showcasing its products and services.
Sanofi has experience with industrial development of all kinds of projects and brings new chemical entities to market.
The Life Science Leader magazine has awarded CEPiA-Sanofi as a worldwide CMO Leader for the third year running.
CEPIA-Sanofi has been awarded the CMO leadership award within the categories quality, reliability, productivity and innovation by Life Science Leader.
CEPiA US and Canada
55 Corporate Drive
United States of America
54/A, Sir Mathuradas Vasanji
400 093 Mumbai
Floor 30, Phase II, Plaza 66, No.1366 Nanjing
CEPiA Eastern Europe and Turkey
130 U Kabelovny
Kerry Center Tower 3
20F, 1228 Yan’An Road
Jing An District